Sequence: YGRKKRRQRRR
| Experiment Id | EXP002351 |
|---|---|
| Paper | Novel miR-122 delivery system based on MS2 virus like particle surface displaying cell-penetrating p |
| Peptide | HIV-Tat (47–57) |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | 100 ng VLP per administration |
| Rna Concentration | |
| Mixing Ratio | |
| Formulation Format | MS2 virus-like particle (VLP) displaying CPP |
| Formulation Components | 2MS-TAT-miR122 VLP (systemic delivery) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | BALB/c nude mice; Hep3B subcutaneous xenograft |
| Administration Route | intravenous (tail vein), twice weekly for 3 weeks |
| Output Type | tumor growth suppression |
| Output Value | Reduced tumor growth/volume and tumor weight; decreased Ki-67; cyclin G1 & Igf1r reduced in tumors |
| Output Units | |
| Output Notes | CT imaging used for tumor volume; H&E necrosis; IHC Ki-67; WB targets |
| Toxicity Notes | No apparent adverse effects reported |
| Curation Notes |